KalVista Pharmaceuticals Inc. has released a corporate presentation highlighting its focus on rare disease therapies, with emphasis on its flagship product, EKTERLY. EKTERLY is described as the first and only oral on-demand therapy for hereditary angioedema $(HAE)$, approved for use in adults and pediatric patients aged 12 years and older. The company reports that EKTERLY is now available in seven key global markets, including the US, EU, UK, Switzerland, Australia, Japan, and Singapore, with plans to expand its indication to younger pediatric patients in 2027. The presentation details the significant burden of HAE, a rare condition characterized by unpredictable and potentially life-threatening swelling attacks, and positions EKTERLY as a foundational treatment option for acute HAE attacks. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kalvista Pharmaceuticals Inc. published the original content used to generate this news brief on January 08, 2026, and is solely responsible for the information contained therein.